Regeneron Pharmaceuticals Files 8-K

TL;DR

REGN filed an 8-K on Feb 4, 2025, covering operations and other events.

AI Summary

Regeneron Pharmaceuticals, Inc. filed an 8-K on February 4, 2025, reporting on results of operations, other events, and financial statements. The filing does not contain specific financial figures or details about the 'other events' in the provided text.

Why It Matters

This filing indicates Regeneron Pharmaceuticals, Inc. is providing updates on its financial condition and other significant events to the SEC.

Risk Assessment

Risk Level: low — The filing is a standard SEC disclosure and does not contain information that inherently increases risk.

Key Players & Entities

• REGENERON PHARMACEUTICALS, INC. (company) — Filer
• 0000872589 (company) — Central Index Key
• February 4, 2025 (date) — Date of Report

FAQ

From the Filing

0001804220-25-000007.txt : 20250204 0001804220-25-000007.hdr.sgml : 20250204 20250204071105 ACCESSION NUMBER: 0001804220-25-000007 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250204 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250204 DATE AS OF CHANGE: 20250204 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 25585296 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 8-K 1 regn-20250204.htm 8-K regn-20250204 0000872589 false 0000872589 2025-02-04 2025-02-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2025 ( February 4, 2025 ) REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 777 Old Saw Mill River Road , Tarrytown , New York 10591-6707 (Address of Principal Executive Offices, including zip code) ( 914 ) 847-7000 Registrant's telephone number, including area code Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock - par value $.001 per share REGN NASDAQ Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02     Results of Operations and Financial Condition. On February 4, 2025, Regeneron Pharmaceuticals, Inc. (" Regeneron " or the " Company ") issued a press release announcing its financial and operating results for the quarter and year ended December 31, 2024. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02. The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated b